Rational approach to diagnostics and treatment of chronic viral hepatitis C


Cite item

Full Text

Abstract

Virus of hepatitis C is the only virus of Hepadnovirus line in the Flaviviridae family which includes RNA. It was found in 199o as a etiologic agent of posttransfusion non-A, non-B hepatitis. Chronic hepatitis C is the main etiologic factor of chronic hepatitis, cirrhosis and hepatocellular carcinoma. In 1999 in Russia the morbidity of hepatitis C was 19,3 on 100 thousand of population. The course of hepatitis is often asymptomatic. In 20-30% of patients with chronic infection it transforms in cirrhosis during the 20 years. The article includes the epidemiology and pathogenesis of chronic hepatitis C and modem algorithms of its diagnostics and treatment.

References

  1. Fried MW, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
  2. Edlin BR. Five million Americans infected with the hepatitis C virus: a corrected estimate. Hepatology 2005;42(Suppl. 1):213A.
  3. Рациональная фармакотерапия заболеваний органов пищеварения. Руководство для практических врачей / Под ред. В.Т. Ивашкина. М, 2003. 1046 с.
  4. Kenny-Walsh K, et al. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999;340:1228-33.
  5. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997;349:825-32.
  6. Seeff LB, et al. Long-term mortality after transfusionassociated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group. N Engl J Med 1992;327:1906-11.
  7. Simmonds P, Bukh J, Combet C, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005;42:962-73.
  8. Tsukuma H, Hiyama T, Tanaka S, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993;328:1797-801.
  9. Hepatitis Surveillance Report N 56 Atlanta: Centers for Disease Control and Prevention; 1996:1-36.
  10. Knodell RG, Ishak KG, Black WC, et. al. Formulation and application of numeral scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepotology 1981;1:431-35.
  11. Seeff LB, et al. National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002. Hepatology 2002;36(5 Suppl. 1):S1-2.
  12. Yeung LT, King SM, Roberts EA. Mother-to-infant transmission of hepatitis C virus. Hepatology 2001;34:223-29.
  13. Zeuzem S. Standart therapie der akuten und chronischen Hepatitis C. Z Gastroenterol 2004;42:714-19.
  14. Чуланов В.П. Молекулярные методы диагностики и оптимизация лечения хронического гепатита С // Клиническая гепатология. 2007. № 2. С. 19-25.
  15. Isaka Y, Nishi Y, Ito Y, et al. Ophthalmic manifestations of interferon therapy in eight patients. Folia Ophthalmol Jpn 1993;44:1054-58.
  16. Manns MP, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2009 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies